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INTRODUCTION
As of May 2020, more than five million people worldwide tested positive for SARS-CoV-2,
among which around 80% display mild or no symptoms (1). There are currently around 4
million people worldwide in this category. According to these and other statistics, asymptomatic
and mildly symptomatic infected pregnant women outnumber those infected women requiring
hospitalization. For example, in a report fromNew York City about 43 pregnant women who tested
positive for SARS-CoV-2 over the course of a 2 week period in March, 2020, the authors found that
86% of COVID-19 pregnant patients presented with mild or no viral-associated symptoms (2).
Reports from China and Europe corroborate that asymptomatic and mildly symptomatic infected
pregnant women outnumber those with severe symptoms. Current studies, however, focus on
severe cases that required hospitalizations. These studies examine maternal and perinatal death
rates, vertical transmission frommother to fetus, and obstetric and neonatal outcomes (3–7). There
remains a gap in knowledge of the impact of the infection in a majority of asymptomatic or mildly
symptomatic women. A recent review reported a high rate of elective preterm cesarean delivery
(8). Maternal and fetal health throughout the trimesters should be examined carefully regardless of
severity of symptoms. More evidence is required to guide obstetric practices.
Hoffmann et al. elucidated the mechanism of host cell entry of SARS-CoV-2. They determined
that angiotensin converting enzyme 2 (ACE2) is the receptor that allows the binding of
SARS-CoV-2 spike proteins and, through this binding process, enters host cells (9). The importance
of ACE2 in SARS-CoV infection was established in the early 2000s. Li et al. first isolated the
protein in SARS-CoV permissive cells and showed that ACE-2 antibodies blocked viral replication
(10). A year later, a research group showed the correlation between susceptibility to SARS-CoV
infection and the level of expression of ACE2 in vitro (11). The study supports the hypothesis that
a higher expression of ACE2 leads to higher risk of SARS-CoV-2 infection. Furthermore, studies
have shown that SARS-CoV infections downregulate ACE2 expression and promotes more severe
disease progression (12–14). ACE2 is expressed in many organs including lung, stomach, kidney,
heart, brain, and reproductive tissues (15, 16). Theoretically, once the virus establishes its primary
infection through the respiratory system, it can spread to any other organs expressing ACE2
through the bloodstream and downregulate the local expression of ACE2. Studies investigating
SARS-CoV-2 infection other than the respiratory system have started to emerge (17, 18). The public
health implications of the spread of SARS-CoV-2 infection from the initial site of infection to the
female reproductive organs, in both pregnant and non-pregnant reproductive age women, are the
focus of this paper.
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SARS-COV-2 INFECTION IN PREGNANCY
AND MATERNAL HEALTH
Asymptomatic and mildly symptomatic pregnant women face
two unique risks posed by SARS-CoV-2 infection due to changes
in ACE2 expression to accommodate hemodynamic changes
in pregnancy. The first risk involves the increased expression
and activity of ACE2 during pregnancy and possible secondary
uteroplacental infection. Increased expression of ACE2 during
pregnancy was suggested by an animal study to play a functional
role in maintaining a normal blood pressure despite an increase
in plasma volume of 20–70% toward the end of pregnancy (16).
ACE2 has been shown to metabolize angiotensin II (Ang II)
to Ang-(1-7) (19). Ang II constricts blood vessels while Ang-
(1-7) dilates vessels. Relative expression of Ang II and Ang-
(1-7), heavily influenced by ACE2 expression, was proposed
to maintain normal blood pressure. Another study confirmed
this finding (19). The study compared mean blood pressure
(MAP) and plasma Ang-(1-7) levels in ACE2 knockout (KO)
and wild type (WT) pregnant mice and found a statistically
significant increase in both MAP and plasma Ang (1-7) level in
ACE2 KO mice (20). The same study also found an association
between ACE2 deficiency and an impaired maternal gestational
weight (20). The uterus and the placenta, with their enhanced
expression and activity of ACE2 during pregnancy (16), may put
pregnant women at an increased risk of establishing a secondary
uteroplacental SARS-CoV-2 infection.
The second risk involves downregulation of ACE2 by the
SARS-CoV-2 virus in pregnancy (14). In the study discussed
above, in which the authors compared MAP and plasma Ang-
(1-7) levels in ACE2 KO and WT pregnant mice, a statistically
significant increase in both MAP and plasma Ang (1-7) level
in ACE2 KO mice was found (20). This finding suggests
another potential risk for the mothers, the potential risk of
developing preeclampsia.
To evaluate the first risk of a secondary uteroplacental
infection, studies should address the relationship between level
of ACE2 expression in placenta and uterine tissues and tissue
susceptibility to SARS-CoV-2 viral invasion. The second risk
of developing preeclampsia needs to be assessed through
human studies comparing the percentage of preeclamptic women
in SARS-CoV-2 positive patients with preeclampsia in non-
COVID-19 patients. A recent article suggested that a high plasma
soluble ACE2 level might be protective for SARS-CoV-2 infection
(21). The authors explained that this paradoxical observation
might be due to the posttranslational events regulating protein
levels and a balance between soluble and membrane-bound
form. These results will need additional confirmation. Normal
hemodynamics in placenta may be affected by viral-induced
downregulation of ACE2 expression in COVID-19 pregnant
women. A study showed a higher Ang II in placenta in ACE2 KO
mice compared to WT mice (20). Previously, an increase in Ang
II in both the maternal and fetal components of the placenta has
been found in human transgenic rat model of preeclampsia (22).
This increase in Ang II was also observed in the chorionic villi
of the placenta of women with preeclampsia (23). The increased
level of Ang II in placenta could lead to placental ischemia.
A recent study of three women with confirmed SARS-CoV-2
infection who delivered by cesarean delivery described placental
pathology (24). All three women had fever, one before delivery
and the other two postpartum. Samples taken from the three
placentas were negative for nucleic acid of SARS-CoV-2. Various
degrees of fibrin deposition inside and in proximity to villi as
well as local syncytial nodule increases were observed in all
three placentas. One displayed massive placental infarction. No
pathological placental changes due to SARS-CoV-2 was found
in the three placentas. Such morphological studies of placenta
should be extended to mildly symptomatic and asymptomatic
women. To understand if the infection compromises blood
flow to the placenta, placental tissue samples need to be
collected from SARS-CoV-2 infected and healthy women. These
samples should be evaluated for signs of ischemia. Furthermore,
the use of ultrasound may demonstrate evidence of placental
vascular compromise. A possible correlation between SARS-
CoV-2 infection and incidence of placental ischemia needs to be
understood through such studies.
In addition, whether there is a progressive increase in risk
throughout the trimesters in developing cardiovascular and
respiratory insufficiency should be addressed. Current published
clinical experience is limited to womenwho developed symptoms
in late third trimester and were delivered shortly after the
diagnosis (8).
SARS-COV-2 INFECTION IN PREGNANCY
AND FETAL HEALTH
In mildly and asymptomatic COVID-19 pregnant women, the
dysregulation of ACE2-Ang-(1-7) and its receptor MasR axis
may have implications for the fetus. This could occur at both
the intrapartum period and long-term. A study in rats showed
that maternal glucocorticoid treatment reduced levels of ACE2
and Ang-(1-7) in rat placenta, specifically in fetal part labyrinth
zone where nutrient and waste exchange occurs in late pregnancy
(25). The animal study further correlated this reduction in
ACE2 and Ang-(1-7) with impaired intrauterine fetal growth. A
recent review of both animal and human studies suggested that
alterations in Ang-(1-7) axis, particularly within the kidney and
brain during perinatal programming, could lead to increased risk
of development of hypertension and cardiovascular disease (26).
To assess if the infection is associated with restricted intrauterine
fetal growth, studies need to monitor ACE2, Ang-(1-7) levels
and the growth of fetus in both infected and healthy women. To
evaluate if fetus born to infected mothers are at a higher risk of
developing hypertension and cardiovascular diseases later in life
compared to fetus born to healthy mothers, the infants need to be
monitored for blood pressure and cardiovascular abnormalities
into early and late adulthood.
SARS-COV-2 INFECTION AND
REPRODUCTIVE HEALTH
Mildly symptomatic and asymptomatic COVID-19 women may
have issues in planning for future reproduction. In particular,
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three issues, sexual transmission of the virus, the use of
contraceptives and the risk of infertility, may be public health
concerns. Recent studies have shown that no SARS-CoV-2 virus
was detected in vaginal fluids or semen in infected individuals
(27, 28). The sample size of both studies, however, is small.
Larger-scale studies remain to be conducted to confirm this
finding. Nevertheless, there is currently no evidence supporting
sexual transmission of the virus. The usage of contraception
should be examined for patients with an ongoing infection.
For SARS-CoV-2 patients with an ongoing infection, whether
estrogen and progesterone contained in contraceptive agents
alters ACE2 expression and induces pregnancy-like risks is
unclear. The dose-response effect of hormones contained
in contraceptive agents on uterine and endometrial ACE2
expression should be studied. In addition, studies should address
whether SARS-CoV-2 infections affect the overall efficacy of
contraception, whether the contraception is via steroid hormones
or by intrauterine devices.
COVID-19 infections may have implications for infertility
patients. The enhanced expression of ACE2 in the placenta and
uterus during early pregnancy (16) after infertility treatment may
make the organs more susceptible to viral entry during mild
or asymptomatic infections. The local placenta-uterus infection
could induce inflammation and subsequent scarring that may
compromise future fertility. In addition, ACE2 is found in human
ovarian follicles and the endometrium (29, 30). As a consequence,
patients with mild or asymptomatic SARS-CoV-2 infections may
have difficulty with their ovarian ovulation induction protocols
or with implantation of embryos in the endometrium. Among
patients without previous history of infertility, whether mild or
asymptomatic SARS-CoV-2 infections increases the infertility
rates should be examined. Thus, for infertility, studies could
include an examination of whether a secondary infection occurs
at a higher rate in mild or asymptomatic infections, whether the
infection affects ovulation induction or embryo implantation and
whether a more general increase in rates of infertility is found in
these patients.
DISCUSSION
The health risks of mild and asymptomatic SARS-CoV-2 infected
women face in pregnancy have not been investigated in detail.
As of May 2020, there have been more than 5 million confirmed
cases worldwide with daily confirmed cases around 90,0001,2.
Assuming that 80% of confirmed cases are asymptomatic and
mildly symptomatic as recent reports suggested (31), there are
1COVID-19 situation update worldwide, as of 6 May 2020. Available at: https://
www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases (accessed
May 6, 2020).
2Daily confirmed COVID-19 cases. Available at: https://ourworldindata.org/
grapher/daily-cases-covid-19 (accessed May 6, 2020).
already close to four million people worldwide in this category.
There is an urgent need to understand what these risks might be
and prepare families for current and future pregnancy challenges.
So far, there have been no conclusive evidence on how the
infection differentially affects pregnant women. They are in fact
advised to take the same precautions as the general public.
Public health initiatives should identify pregnant women infected
with Covid-19 with antibody tests and monitor maternal and
fetal health closely. Initiatives should also include non-pregnant
women to be monitored for future reproductive issues.
There is a theoretical public health concern for SARS-CoV-2
to impact both a current pregnancy and future reproduction in
mildly symptomatic and asymptomatic women. This theoretical
issue is rooted in two findings that have been substantiated by
several studies. The first is the association between the SARS-
CoV-2 infection and disrupted ACE2 expression. Disrupted
ACE2 expression is likely to lead to dysregulation in ACE2
Ang-(1-7) axis. The other finding is an association between
dysregulated ACE2 Ang-(1-7) axis and impaired maternal and
fetal health. Combining the two findings, we hypothesize that
SARS-CoV-2 impairs cardiovascular adaptation of mothers,
normal hemodynamic regulation of placenta, fetal growth and
long-term cardiovascular health, as well as reproductive health
of women in general.
The significance of ACE2 in the infection of SARS-CoV-
2 is clear. Current evidences are mainly derived from animal
studies. Future studies may consider distinguishing the function
of soluble and membrane-bound form of ACE2 in viral invasion,
early and late stages of the infection. Regardless of whether
soluble and membrane bound forms of ACE2 play distinct roles,
we think that ACE2 Ang-(1-7) axis is disrupted to different
degrees during the infection. And this becomes a critical question
that needs to be addressed in future studies.
As studies continue to shed light on the effect of the infection
on different organ systems, they should engage the research
community, clinicians, and the public to reassess the impact
of the infection on reproduction. Based on evidence discussed
here, we think that there are effects on mothers, placenta, and
the fetus throughout the trimesters. In addition, we hypothesize
that these effects may extend into future reproduction of mildly
symptomatic and asymptomatic COVID-19 women. Given the
risks associated with asymptomatic SARS-CoV-2 infections as
well as inconclusive evidence surrounding vertical transmission,
women of reproductive age may need to be advised about
the theoretical risks to the mother and fetus until more
is known.
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